Calithera Biosciences Cultura de la Empresa

Dr. Molineaux has served as our President, Chief Executive Officer, and as a member of our board of directors since she co-founded Calithera in 2010. Dr. Molineaux co-founded Proteolix, a biopharmaceutical company, where she served in various roles, including Chief Executive Officer, and Chief Scientific Officer until Proteolix’s acquisition by Onyx Pharmaceuticals. Prior to Proteolix, Dr. Molineaux served as Vice President of Biology at Rigel Pharmaceuticals, a drug development company. Dr. Molineaux began her career as a scientist in the Immunology group at Merck. Dr. Molineaux currently serves as a member of the board of directors of Geron Corporation, Theravance Biopharma, and Smith College. She formerly served as member of the board of directors of We Teach Science, and the California Life Sciences Association. Dr. Molineaux holds a B.S. in Biology from Smith College and a Ph.D. in Molecular Biology from Johns Hopkins University, and she completed a postdoctoral fellowship at Columbia University.

Ms. Sumita Ray has been the Senior Vice President, General Counsel and Chief Compliance Officer at Calithera Biosciences, Inc. since October 3, 2017. Ms. Ray has a breadth of knowledge in FDA regulatory law, global health care law and compliance, brand support, product launches, collaborations and alliances. Ms. Ray served as the Chief Compliance Officer, Head of Healthcare and Regulatory Law and Associate General Counsel of Healthcare Law at Pharmacyclics LLC (alternate name, Pharmacyclics Inc.), where she supported the Pharmacyclics through the global approval and launch of Imbruvica in multiple indications Ms. Ray joined Pharmacyclics in April 2013. She has more than 17 years of legal, regulatory and compliance experience in the pharmaceutical and biotech industries. Ms. Ray's legal and compliance practice involves collaboration with the clinical development, medical affairs and commercial business units, among others, on strategies to meet business goals in an ethical, legally sound and compliant manner. Ms. Ray started her career as a pharmaceutical and products liability litigator at Montgomery, McCracken, Walker and Rhoads LLP. She was at Elan Pharmaceuticals in San Francisco, where she was a member of the company's Legal Leadership Team and Head of the BioNeurology and Regulatory Law Group , leading and managing a team of lawyers and paralegals in global support of Elan's pipeline and marketed products. In 2010, Ms. Ray was significantly involved in the negotiation and settlement of Elan's Corporate Integrity Agreement with the Office of Inspector General and the subsequent drafting, implementing and training of the global business on key policies and procedures related to a Global Compliance program. Prior to joining Elan, Ms. Ray was in the legal department as Corporate Counsel of AstraZeneca Pharmaceuticals for 2.5 years, followed by Genentech for 3 years, where Ms. Ray was the lead Legal Counsel for each respective company's blockbuster drug product in primary care and oncology and engaged in several FDA label negotiations, approvals and subsequent product launches. Prior to moving in-house, Ms. Ray spent 5 years as a pharmaceutical and products liability litigator at a major Philadelphia-based law firm, where she spent a significant amount of time on the FEN-PHEN products liability case, among other historic pharmaceutical cases. Ms. Ray holds a Juris Doctor from Temple University Law School and a bachelor of science in microbiology from the University of Arizona. She is licensed to practice law in Pennsylvania, New Jersey and California.

Dr. Keith Orford, M.D., Ph.D., has been Senior Vice President of Clinical Development at Calithera Biosciences, Inc. since May 13, 2016 and served as its Vice President of Clinical Development since January 30, 2015 until May 13, 2016. Dr. Orford joined the Calithera Biosciences following a distinguished career in oncology pharmaceuticals development, including senior clinical roles with GlaxoSmithKline (GSK) and Merck. At Calithera, Dr. Orford is responsible for clinical development of CB-839, its lead oral product candidate in tumor metabolism, as well as subsequent clinical development programs. Dr. Orford joined Calithera from GSK where he was the Clinical Development Lead in the Immuno-Oncology and Combinations Development Performance Unit, overseeing the clinical activities on multiple early stage clinical trials with targeted agents and novel immune-based therapies. Prior to GSK, Dr. Orford was at Merck, where he worked on early clinical development programs across oncology and other therapeutic areas. He completed his clinical training in Internal Medicine and postdoctoral work at Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), studying the epigenetic regulation of hematopoietic and embryonic stem cell differentiation, becoming a Research Fellow and then an Instructor at MGH/HMS. Dr. Orford received his undergraduate degree, M.D. and Ph.D. from Georgetown University.

Christopher Molineaux serves as the Sr. VP Development of Calithera Biosciences. Christopher started at Calithera Biosciences in Apr of 2013. Christopher currently resides in the San Francisco Bay Area.

Keith Orford serves as the Senior Vice President, Clinical Development of Calithera Biosciences. Keith started at Calithera Biosciences in Jan of 2015. Keith currently resides in the Greater Philadelphia Area.